Crown Bioscience has announced the beginning of the Eurostars Myeloid SIGNATUREs (MY-SIGNATURE) project. This initiative aims to tackle prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), a disease that leads to approximately 110,000 fatalities each year in Europe. The project, which received a €1.75 million grant, will focus on developing a novel liquid biopsy test—the first to detect intratumoral myeloid-derived suppressor cell (MDSC) infiltration—and could become pivotal in overcoming therapy resistance, a substantial challenge in cancer treatment.

Crown Bioscience is joined by Novigenix, the project's lead partner, and the expertise from Radboud University Medical Centre to develop the MYELO-SCAN test.

Ludovic Bourré, PhD, VP of Research and Innovation at Crown Bioscience, commented: "We are proud to be part of this consortium, which not only aligns with our commitment to providing innovative solutions but also establishes a foundation for transforming prostate cancer treatment. By advancing how we stratify and treat mCRPC patients, we are not just enhancing patient care today—we are paving the way for future breakthroughs."

For details, please see the announcement.
Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biopsy Test | JSR Life Sciences Newsroom